Vanderbilt Network Lead Academic Participating Site for the NCTN

范德比尔特网络 (Vanderbilt Network) 主导 NCTN 学术参与网站

• 批准号: 9889083
• 负责人: JORDAN D BERLIN
• 金额: $ 48.73万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-07 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9889083
• 关键词: Academic Medical Centers; Advanced Malignant Neoplasm; Advisory Committees; Alabama; Antineoplastic Agents; Appointment; Area; Authorship; Automobile Driving; Award; Basic Science; Berlin; Biology; Breast; Budgets; Cancer Center; Cancer Patient; Catchment Area; Cessation of life; Clinical Cancer Center; Clinical Investigator; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Collaborations; Collection; Communities; Compassion; Comprehensive Cancer Center; Conduct Clinical Trials; Country; Data; Death Rate; Department chair; Development; Diagnosis; Discipline; Discipline of obstetrics; Disease; Early Detection Research Network; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Education and Outreach; Enrollment; Ensure; Faculty; Funding; Goals; Grant; Growth; Gynecology; Health; Human; Image; Immunology; Immunotherapy; Incidence; Infection; Inflammation; Informatics; Infrastructure; Institutes; Institution; Institutional Review Boards; Jordan; Kentucky; Knowledge; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Manuscripts; Medical; Medicine; Mentors; Mentorship; Mission; Mutation; NCI Center for Cancer Research; National Cancer Institute; National Clinical Trials Network; Obesity; PD-1/PD-L1; PDL1 inhibitors; Patient-Centered Care; Patients; Phase II/III Clinical Trial; Physicians; Prevention; Prevention education; Principal Investigator; Process; Protocols documentation; Radiology Specialty; Research; Research Activity; Research Personnel; Research Priority; Research Support; Resource Sharing; Resources; Role; Science; Scientist; Services; Site; System; Technology; Tennessee; Time; Tobacco use; Training; Translational Research; Translations; United States; Universities; Work; cancer care; cancer clinical trial; cancer genomics; cancer therapy; data submission; design; drug discovery; early phase trial; evidence base; gastrointestinal; improved; improved outcome; innovation; inter-institutional; interest; investigator-initiated trial; medical specialties; meetings; member; multidisciplinary; next generation; novel; patient oriented; programs; radiological imaging; recruit; resistance mechanism; success; targeted treatment; tumor; web site

PROJECT SUMMARY/ABSTRACT Vanderbilt-Ingram Cancer Center (VICC) is a matrix cancer center within Vanderbilt University Medical Center (VUMC). VICC has been part of the cooperative group system for over 27 years, and a Lead Academic Participating Site since the inception of the National Clinical Trials Network (NCTN). Throughout the years, we have integrated our physicians into leadership roles and our basic science into investigator-initiated trials, as well as enrolled patients onto clinical trials. Additionally, VICC has a long track record of leadership, both scientific and administrative, within the cooperative groups/NCTN, and helping junior faculty in clinical trial development. VICC brings great strengths to the NCTN, including two SPORE grants, an EDRN grant, a world class Institute of Imaging Science, eight highly funded scientific programs and an Early Therapeutics Clinical Trial Network (ETCTN) grant where successful early phase trials can be integrated into the NCTN. Our Personalized Cancer Medicine Initiative (PCMI) is dedicated to matching the appropriate therapy to the genetic changes, or mutations, that are driving the growth of cancers, with an active research component investigating mechanisms of resistance to targeted therapies. The key informatics of the VICC PCMI is MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations. With the development of PD-1/PD-L1 inhibitors and novel immune therapies on the horizon, VICC has recruited top researchers in immunology. Those top researchers in collaboration with other VUMC investigators created the Vanderbilt Institute for Infection, Immunology and Inflammation (VI4) with an overall mission to train the next generation scientists and physicians and make fundamental discoveries in the areas of infection biology, immunology and inflammation with the goal of increasing knowledge and improving human health. VICC clinicians and scientists are academic leaders in their respective disciplines and will continue to significantly contribute to the NCTN goals with the objective to improve the outcomes for cancer patients. The VICC selected Dr. Jordan Berlin, MD, as Principal Investigator to continue leading the efforts of the institution to integrate its scientific, academic and patient resources into the NCTN. He has been involved extensively in the cooperative groups/NCTN in conduct of clinical trials, mentorship and leadership. To assist Dr. Berlin with the conduct of this grant, VICC created two advisory boards, Internal Advisory Board (IAB) and NCTN Executive Committee (NEC), whose membership includes a broad representation of medical disciplines and disease interests across VICC and VUMC. The IAB assures the optimal use of the grant, such as budget review, assuring multidisciplinary involvement, and participation throughout the NCTN. The NEC implements operational functions, such as trial opening, accrual and mentoring. Operationally, the NEC has actively managed NCTN trial opening, accruals and participation across disciplines and groups. Both the IAB and NEC work to integrate VICC science into the NCTN. The VICC Clinical Trials Shared Resource and its NCTN team ensures that regulatory, biospecimen, radiology and data submissions are timely and highly accurate. An extensive plan to further advance the integration of the NCTN into the VICC clinical research enterprise and VICC research into the NCTN is detailed in the grant, including the new appointment of Dr. Berlin to the role of Associate Director for Clinical Research Strategy and Shared Resources. This is a new role for VICC, designed to allow coordination of clinical research priorities across all VICC programs and to increase the translation of VICC science into clinical trials. For this grant, Dr. Berlin’s new role will help to strengthen the prioritization of NCTN trials across the institution.

项目总结/摘要 范德比尔特-英格拉姆癌症中心（VICC）是范德比尔特大学医学中心内的矩阵癌症中心 （VUMC）. VICC已经成为合作团体系统的一部分超过27年，并且是一个领先的学术机构。 自国家临床试验网络（NCTN）成立以来的参与研究中心。这些年来，我们 已经将我们的医生整合到领导角色中，将我们的基础科学整合到制药商发起的试验中， 以及临床试验的患者。此外，VICC拥有长期的领导记录， 科学和行政，在合作小组/NCTN，并帮助初级教师在临床试验 发展VICC为NCTN带来了巨大的优势，包括两项SPORE赠款、一项EDRN资助、一个世界 一级成像科学研究所，八个高度资助的科学项目和一个早期治疗临床 试验网络（ETCTN）资助，成功的早期试验可以整合到NCTN中。我们 个性化癌症医学倡议（PCMI）致力于将适当的治疗与遗传相匹配。 改变或突变，这是推动癌症的增长，与积极的研究组成部分调查 对靶向治疗的耐药机制。VICC PCMI的关键信息学是MyCancerGenome， 一个网站，不仅告知医生最新的癌症基因组学，而且还提供试验， 肿瘤携带可操作的基因改变的患者。随着PD-1/PD-L1抑制剂的发展， 和新的免疫疗法的地平线上，VICC招募了免疫学的顶级研究人员。那些顶尖 研究人员与其他VUMC研究人员合作创建了范德比尔特感染研究所， 免疫学和炎症（VI 4）的总体使命是培养下一代科学家， 在感染生物学、免疫学和炎症领域有重大发现 以增加知识和改善人类健康为目标。VICC临床医生和科学家 在各自学科的学术领导者，并将继续显着贡献NCTN的目标 目的是改善癌症患者的预后。 VICC选择医学博士Jordan柏林作为主要研究者，继续领导 该机构将其科学，学术和患者资源整合到NCTN中。他参与 广泛参与合作小组/NCTN的临床试验、指导和领导工作。协助 博士柏林随着这项赠款的进行，维也纳国际中心设立了两个咨询委员会，内部咨询委员会（IAB）和 NCTN执行委员会（NEC），其成员包括医学学科的广泛代表 以及VICC和VUMC的疾病兴趣。IAB确保赠款的最佳使用，例如预算 审查，确保多学科参与，并参与整个NCTN。NEC执行 业务职能，如试运行、权责发生制和指导。在业务上，NEC积极 管理NCTN试验的开放、应计费用和跨学科和小组的参与。IAB和NEC 致力于将VICC科学融入NCTN。VICC临床试验共享资源及其NCTN团队 确保监管、生物标本、放射学和数据提交的及时性和高度准确性。 一项广泛的计划，以进一步推进NCTN与VICC临床研究企业的整合， VICC对NCTN的研究在拨款中有详细说明，包括柏林博士的新任命， 临床研究策略和共享资源副总监。这是VICC的一个新角色， 旨在协调所有VICC项目的临床研究优先事项，并增加 将VICC科学转化为临床试验。对于这笔赠款，柏林博士的新角色将有助于加强 在整个机构中优先考虑NCTN试验。